Article
Clinical Neurology
Assaf Berger, Juan Diego Alzate, Kenneth Bernstein, Reed Mullen, Sean McMenomey, Daniel Jethanemest, David R. Friedmann, Eric Smouha, Erik P. Sulman, Joshua S. Silverman, J. Thomas Roland, John G. Golfinos, Douglas Kondziolka
Summary: This study evaluates hearing outcomes in patients with vestibular schwannoma (VS) during the modern era of cochlear dose restriction. The results show that factors such as age, baseline GR score, cochlear dose, and biological effective dose are correlated with hearing preservation. Increased tumor-free canal space is associated with better outcomes. Furthermore, patients who meet specific criteria have higher hearing preservation rates compared to the rest of the population.
Article
Medicine, Research & Experimental
Manu Shrivastava, Beatrice Emmanouil, Rajeev Mathew, Dorothy Halliday, Allyson Parry, Jane Halliday, Samuel Mackeith
Summary: This study retrospectively analyzed the long-term control rates and hearing outcomes of NF2-related growing vestibular schwannoma patients treated with SRS/FRT. The results showed that SRS/FRT had a good efficacy in tumor control and treatment control, and could preserve hearing in some patients.
Article
Clinical Neurology
Jeffery R. Head, Othman Bin-Alamer, Zhishuo Wei, Kaitlin Waite, Nishant Agrawal, Arka N. Mallela, Andrew Faramand, Zachary C. Gersey, Ajay Niranjan, L. Dade Lunsford, Hussam Abou-Al-Shaar
Summary: Through a retrospective study, it was found that stereotactic radiosurgery (SRS) can effectively control tumors and symptoms in octogenarian patients with vestibular schwannomas (VS).
Article
Clinical Neurology
Stylianos Pikis, Georgios Mantziaris, Rithika Kormath Anand, Ahmed M. Nabeel, Darrah Sheehan, Kimball Sheehan, Wael A. Reda, Sameh R. Tawadros, Khaled Abdelkarim, Amr M. N. El-Shehaby, Reem Emad Eldin, Selcuk Peker, Yavuz Samanci, Tehila Kaisman-Elbaz, Herwin Speckter, Wenceslao Hernandez, Julio Isidor, Manjul Tripathi, Renu Madan, Brad E. Zacharia, Lekhaj C. Daggubati, Nuria Martinez Moreno, Roberto Martinez alvarez, Anne-Marie Langlois, David Mathieu, Christopher P. Deibert, Vivek R. Sudhakar, Christopher P. Cifarelli, Denisse Arteaga Icaza, Daniel T. Cifarelli, Zhishuo Wei, Ajay Niranjan, Gene H. Barnett, L. Dade Lunsford, Greg N. Bowden, Jason P. Sheehan
Summary: In this retrospective multicenter study, the authors evaluated the tumor control and patient outcomes of primary, single-session stereotactic radiosurgery (SRS) treatment for Koos grade IV vestibular schwannomas (VSs). The results showed that single-session SRS treatment is a safe and effective method for obtaining tumor control in patients with non-life-threatening or incapacitating symptoms of Koos grade IV VS. A prescription dose of less than 13 Gy is recommended to reduce the incidence of post-SRS facial palsy.
JOURNAL OF NEUROSURGERY
(2023)
Article
Clinical Neurology
Zane Schnurman, Jason Gurewitz, Eric Smouha, Sean O. McMenomey, J. Thomas Roland, John G. Golfinos, Douglas Kondziolka
Summary: Through propensity score matching, this study found no significant difference in the loss of class A or serviceable hearing between patients managed with SRS or observation alone when controlling for potential confounders.
Article
Clinical Neurology
Othman Bin-Alamer, David Fogg, Zhishuo Wei, James Duehr, Arka N. Mallela, Ajay Niranjan, L. Dade Lunsford, Hussam Abou-Al-Shaar
Summary: This study retrospectively reviewed 2058 patients who underwent stereotactic radiosurgery for vestibular schwannomas, and found a cumulative incidence rate of 0.26% for intra-tumoral hemorrhage. Most patients could achieve stable or improved condition through observation or delayed resection, although one patient required urgent surgical intervention.
JOURNAL OF NEUROSURGERY
(2023)
Review
Clinical Neurology
Max Whitmeyer, Bledi C. Brahimaj, Andre Beer-Furlan, Sameer Alvi, Madeline J. Epsten, Fred Crawford, Richard W. Byrne, R. Mark Wiet
Summary: This study focused on evaluating the outcomes of salvage microsurgery (MS) after stereotactic radiosurgery (SRS) for vestibular schwannomas (VS) based on a review of 20 studies and 300 cases. The primary indication for salvage surgery was tumor growth after an average of 39.4 months post-radiation. The study found no significant differences in outcomes based on surgical approach, but patients who underwent subtotal resection (STR) showed better House-Brackmann outcomes compared to those who had gross-total resection (GTR).
JOURNAL OF NEUROSURGERY
(2021)
Article
Clinical Neurology
Conrad Josef Villafuerte, David B. Shultz, Normand Laperriere, Fred Gentili, Robert Heaton, Monique van Prooijen, Michael D. Cusimano, Mojgan Hodaie, Michael Schwartz, Alejandro Berlin, David Payne, Suneil K. Kalia, Mark Bernstein, Justin Wang, Gelareh Zadeh, Julian Spears, Derek S. Tsang
Summary: Calibration dose rate and BED were not significantly associated with tumor control or edema post SRS treatment for acoustic neuroma. Salvage SRS and larger tumors were correlated with higher local failure rates, while cystic tumors were associated with lower local failure rates.
WORLD NEUROSURGERY
(2021)
Article
Oncology
A. Gawish, M. Walke, B. Roellich, H. -J. Ochel, T. B. Brunner
Summary: A retrospective analysis was conducted on the long-term results of hypofractionated stereotactic radiation therapy (HSRT) for vestibular schwannomas. The majority of patients showed a positive response to HSRT, while around 38% of patients had stable disease without any response. The local control rates at 3, 5, and 7 years were 96%, 95%, and 94% respectively. Temporary grade 2 toxicity was observed in some patients, but no cases of radiation necrosis were reported.
Article
Oncology
Daniel Ruess, Betina Schuetz, Eren Celik, Christian Baues, Stephanie T. Juenger, Volker Neuschmelting, Alexandra Hellerbach, Markus Eichner, Martin Kocher, Maximilian I. I. Ruge
Summary: After stereotactic radiosurgery (SRS) for vestibular schwannomas (VS), the temporary increase in tumor size complicates the differentiation between treatment-related changes (pseudoprogression) and tumor recurrence (progressive disease). Therefore, modifying RANO criteria is proposed to facilitate further observation of VS during follow-up.
Review
Clinical Neurology
Elizabeth J. Buss, Tony J. C. Wang, Michael B. Sisti
Summary: Management options for newly diagnosed vestibular schwannoma (VS) include observation, surgery, or radiation. There are no randomized trials to guide management of patients with VS. This article reviews the role of stereotactic radiosurgery in the management of newly diagnosed VS.
NEUROSURGICAL REVIEW
(2021)
Review
Oncology
Umberto Tosi, Omri Maayan, Anjile An, Miguel E. Tusa Lavieri, Sergio W. Guadix, Antonio P. DeRosa, Paul J. Christos, Susan Pannullo, Philip E. Stieg, Andrew Brandmaier, Jonathan P. S. Knisely, Rohan Ramakrishna
Summary: Treatment of NF2-associated vestibular schwannomas remains challenging, as stereotactic radiosurgery results in impaired hearing and worse cranial nerve comorbidities.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Oncology
Chloe Dumot, Stylianos Pikis, Georgios Mantziaris, Zhiyuan Xu, Rithika Kormath Anand, Ahmed M. Nabeel, Darrah Sheehan, Kimball Sheehan, Wael A. Reda, Sameh R. Tawadros, Khaled Abdel Karim, Amr M. N. El-Shehaby, Reem M. Emad Eldin, Selcuk Peker, Yavuz Samanci, Tehila Kaisman-Elbaz, Herwin Speckter, Wenceslao Hernandez, Julio Isidor, Manjul Tripathi, Renu Madan, Brad E. Zacharia, Lekhaj C. Daggubati, Nuria Martinez Moreno, Roberto Martinez Alvarez, Anne-Marie Langlois, David Mathieu, Christopher P. Deibert, Vivek R. Sudhakar, Christopher P. Cifarelli, Denisse Arteaga Icaza, Daniel T. Cifarelli, Zhishuo Wei, Ajay Niranjan, Gene H. Barnett, L. Dade Lunsford, Greg N. Bowden, Jason P. Sheehan
Summary: Single-session SRS is a safe and effective alternative to surgical resection in selected patients <= 45 years old, especially for those with medical co-morbidities and who decline resection. The treatment showed good tumor control and neurological outcomes, with some cases experiencing early tumor enlargement, adverse radiation effects, and new-onset hydrocephalus.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Oncology
Putipun Puataweepong, Mantana Dhanacha, Rawee Ruangkanchanasetr, Keeratikarn Boonyawan, Ake Hansasuta, Kriangsak Saetia, Pornpan Yongvithisatid
Summary: This study retrospectively analyzed the clinical outcomes of neurofibromatosis 2-related vestibular schwannoma patients treated with Robotic HSRT. The results showed excellent long-term tumor control with Robotic HSRT, but hearing preservation remains a major concern.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Clinical Neurology
Chloe Dumot, Stylianos Pikis, Georgios Mantziaris, Zhiyuan Xu, Sam Dayawansa, Rithika Kormath Anand, Ahmed M. Nabeel, Darrah Sheehan, Kimball Sheehan, Wael A. Reda, Sameh R. Tawadros, Khaled Abdel Karim, Amr M. N. El-Shehaby, Reem M. Emad Eldin, Selcuk Peker, Yavuz Samanci, Tehila Kaisman-Elbaz, Herwin Speckter, Wenceslao Hernandez, Julio Isidor, Manjul Tripathi, Renu Madan, Brad E. Zacharia, Lekhaj C. Daggubati, Nuria Martinez Moreno, Roberto Martinez Alvarez, Anne-Marie Langlois, David Mathieu, Christopher P. Deibert, Vivek R. Sudhakar, Christopher P. Cifarelli, Denisse Arteaga Icaza, Daniel T. Cifarelli, Zhishuo Wei, Ajay Niranjan, Gene H. Barnett, L. Dade Lunsford, Greg N. Bowden, Jason P. Sheehan
Summary: This study aimed to report the clinical and radiological outcomes after single-session stereotactic radiosurgery (SRS) for Koos IV vestibular schwannomas (VS) in patients aged 65 and above. The results showed that SRS had good efficacy in tumor control and cranial nerve function in these patients.
ACTA NEUROCHIRURGICA
(2023)
Article
Ophthalmology
Johannes Gollrad, Christopher Rabsahl, Antonia M. Joussen, Andrea Stroux, Volker Budach, Dirk Boehmer, Alexander Boeker
Summary: This study investigated the impact of adjuvant local interventions on the quality of life in patients with uveal melanoma after proton therapy. The results showed that these interventions did not have long-lasting effects on the patients' quality of life.
OCULAR ONCOLOGY AND PATHOLOGY
(2022)
Article
Oncology
Marcus Beck, Peter Wust, Eva Oberacker, Alexander Rattunde, Tom Paessler, Benjamin Chrzon, Paraskevi Danai Veltsista, Jacek Nadobny, Ruben Pellicer, Enrico Herz, Lukas Winter, Volker Budach, Sebastian Zschaeck, Pirus Ghadjar
Summary: Objective hyperthermia has been confirmed as an enhancer of radio- and/or chemotherapy through various trials, with positive results from capacitive hyperthermia systems (CHS) observed despite lower specific absorption rates (SAR) in deep regions compared to established techniques. Phantom measurements and simulations for commercial CHS Celsius42 showed effective SAR reaching depths of 6-8 cm in a homogeneous phantom and 10-20 W/kg achieved in intermediate to deep regions despite the presence of a fat layer. The application of CHS is feasible for certain pelvic and abdominal tumor patients, as well as for heating superficial and medium-deep tumors and some bone metastases.
INTERNATIONAL JOURNAL OF HYPERTHERMIA
(2022)
Article
Oncology
Felix Ehret, David Kaul, Markus Kufeld, Clara Vom Endt, Volker Budach, Carolin Senger, Christoph Fuerweger, Alfred Haidenberger, Alexander Muacevic
Summary: This study analyzed the outcomes of robotic-assisted short-course stereotactic body radiotherapy (SBRT) for adrenal gland metastases (AGMs). The results showed that short-course SBRT is an effective and safe treatment modality for AGMs, with sporadic and manageable treatment-associated side effects. The study suggests that short-course SBRT can be a preferable and time-saving treatment option for AGMs if an adequate biologically effective dose can be safely applied.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Letter
Biochemistry & Molecular Biology
Alexander H. Thieme, Maximilian Gertler, Mirja Mittermaier, Matthias I. Groeschel, Jonathan H. Chen, Brar Piening, Justus Benzler, Daniel Habenicht, Volker Budach, Olivier Gevaert
Article
Oncology
Shivaprasad Patil, Annett Linge, Marianne Grosser, Fabian Lohaus, Volker Gudziol, Max Kemper, Alexander Nowak, Dominik Haim, Inge Tinhofer, Volker Budach, Maja Guberina, Martin Stuschke, Panagiotis Balermpas, Claus Roedel, Henning Schaefer, Anca-Ligia Grosu, Amir Abdollahi, Juergen Debus, Ute Ganswindt, Claus Belka, Steffi Pigorsch, Stephanie E. Combs, Simon Boeke, Daniel Zips, Gustavo B. Baretton, Michael Baumann, Mechthild Krause, Steffen Loeck
Summary: This study developed and validated a novel prognostic 6-gene signature for predicting loco-regional control of HPV-negative HNSCC patients treated with postoperative radio(chemo)therapy. The signature showed predictive significance in both training and validation cohorts, and could improve personalized clinical trials for radiotherapy.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Oncology
Johannes Gollrad, Nevenka Korpusik, Christopher Rabsahl, Dirk Boehmer, Angela Besserer, Ulrike Grittner, Alexander Boeker, Ulrich Keilholz, Antonia Joussen, Volker Budach, Ute Goerling
Summary: The decision-making process for cytogenetic testing in uveal melanoma patients is influenced by various factors, including treating physicians, internet resources, and baseline anxiety. Patients are likely to reject testing when they worry that knowing the result will have unintended consequences on their life.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Dirk Boehmer, Alessandra Siegmann, Sophia Scharl, Christian Ruf, Thomas Wiegel, Manuel Krafcsik, Reinhard Thamm
Summary: This study found that increasing the radiation dose during salvage radiotherapy could reduce the risk of prostate cancer relapse, suggesting that failed prostatectomy patients might benefit from dose-escalated salvage radiotherapy to improve tumor control and postpone secondary treatments. However, longer follow-ups are needed for a comprehensive recommendation.
Article
Oncology
Anne Kluge, Stefanie Ehrbar, Melanie Grehn, Jens Fleckenstein, Wolfgang W. Baus, Frank-Andre Siebert, Achim Schweikard, Nicolaus Andratschke, Michael C. Mayinger, Judit Boda-Heggemann, Daniel Buergy, Eren Celik, David Krug, Boldizsar Kovacs, Ardan M. Saguner, Boris Rudic, Paula Bergengruen, Leif-Hendrik Boldt, Annina Stauber, Adrian Zaman, Hendrik Bonnemeier, Jurgen Dunst, Volker Budach, Oliver Blanck, Felix Mehrhof
Summary: This study aimed to provide a benchmark for treatment planning of cardiac radioablation in multicenter clinical studies and establish an objective ranking system for plan quality. By collecting and analyzing treatment plans developed using different platforms and techniques in different centers, it was found that although most plans deviated slightly from the study guidelines, the overall plan quality was acceptable. VMAT plans had steeper dose gradients in the high-dose region, while plans for robotic arm LINAC had smaller low-dose regions.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
Orit Kaidar-Person, Catherine Fortpied, Sandra Hol, Caroline Weltens, Carine Kirkove, Volker Budach, Karine Peignaux-Casasnovas, Femke van der Leij, Ernest Vonk, Mariacarla Valli, Nicola Weidner, Matthias Guckenberger, Eveline Koiter, Alain Fourquet, Harry Bartelink, Henk Struikmans, Philip Poortmans
Summary: This study analyzed the effects of different techniques of IM-MS lymph node irradiation on long-term outcomes in breast cancer patients. The results showed that using more individualized radiation therapy techniques can improve oncological outcomes without increasing the risk of late side effects.
RADIOTHERAPY AND ONCOLOGY
(2022)
Review
Oncology
Arndt-Christian Mueller, Daniel M. Aebersold, Clemens Albrecht, Dirk Boehmer, Michael Flentje, Ute Ganswindt, Pirus Ghadjar, Nina-Sophie Schmidt-Hegemann, Stefan Hoecht, Tobias Hoelscher, Peter Niehoff, Michael Pinkawa, Felix Sedlmayer, Frank Wolf, Constantinos Zamboglou, Daniel Zips, Thomas Wiegel
Summary: The indication for radiation therapy of the primary prostate tumor in patients with synchronous distant metastases with low metastatic burden has been revised based on randomized evidence. The STAMPEDE trial showed a survival benefit of 8% after 3 years for patients treated with standard of care and additional radiotherapy of the primary tumor. The STOPCAP meta-analysis confirmed the benefit of local radiotherapy for up to 4 bone lesions.
STRAHLENTHERAPIE UND ONKOLOGIE
(2022)
Article
Oncology
Shivaprasad Patil, Annett Linge, Hannah Hiepe, Marianne Grosser, Fabian Lohaus, Volker Gudziol, Max Kemper, Alexander Nowak, Dominik Haim, Inge Tinhofer, Volker Budach, Maja Guberina, Martin Stuschke, Panagiotis Balermpas, Jens von Der Grun, Henning Schafer, Anca-Ligia Grosu, Amir Abdollahi, Jurgen Debus, Ute Ganswindt, Claus Belka, Steffi Pigorsch, Stephanie E. Combs, Simon Boeke, Daniel Zips, Korinna Johrens, Gustavo B. Baretton, Michael Baumann, Mechthild Krause, Steffen Lock
Summary: This study aimed to identify high-risk head and neck squamous cell carcinoma patients who may benefit from additional concurrent chemotherapy after surgery and postoperative radiotherapy. The developed gene signature helped stratify patients into risk groups and indicated potential benefit from postoperative radiochemotherapy.
Article
Gastroenterology & Hepatology
Johannes Lauscher, Sebastian Stintzing, Dirk Boehmer
Summary: This article summarizes the current randomized trials on total neoadjuvant therapy (TNT) for locally advanced rectal cancer and discusses the indications, optimal sequence of therapy, and therapeutic regimen. The findings suggest that TNT can improve oncological outcomes in patients with lower and middle third rectal cancer and is the preferred treatment option for certain patients.
Article
Oncology
Nikolaj Frost, Julia Roeper, Janna-Lisa Velthaus, Matthias Raspe, Elisabeth Olive, Alexander Schmittel, Bernd Schmidt, David Wasilewski, Julia Onken, Heike Lueders, Martin Witzenrath, Carolin Senger, Dirk Boehmer, Sonja Loges, Frank Griesinger, Dominik P. Modest, Christian Grohe
Summary: This study conducted a multicenter analysis on patients with oligometastatic lung cancer and found that controlling brain metastasis played a crucial role, and repeated local ablative therapy can effectively prolong the survival time.
Meeting Abstract
Oncology
V. Ehrhardt, F. Ehret, A. Kluge, D. Boehmer, V. Budach, A. Gruen
STRAHLENTHERAPIE UND ONKOLOGIE
(2022)